BrainsWay Ltd. ($BWAY) reported its Q4 2025 earnings, with the company’s Chief Executive Officer, Hadar Levy, and Chief Financial Officer, Ido Marom, leading the call. The earnings call, which took place on March 11, 2026, at 8:30 AM EDT, provided insight into the company’s performance and future prospects, with $BWAY shares reacting to the news.
The Q4 2025 earnings call was highly anticipated, as investors sought to understand the company’s progress in the development and commercialization of its non-invasive transcranial magnetic stimulation (TMS) technology. BrainsWay Ltd. has been at the forefront of this technology, which has shown promise in treating various neurological and psychiatric disorders. The company’s BrainsWay Ltd. has been working to expand its product offerings and increase its market share, with a focus on the healthcare sector.
In recent years, $BWAY has made significant strides in the development of its TMS technology, with a focus on treating conditions such as depression, anxiety, and obsessive-compulsive disorder. The company has also been working to expand its global reach, with partnerships and collaborations in key markets. As the healthcare technology sector continues to evolve, $BWAY is well-positioned to capitalize on emerging trends and opportunities.
The earnings call provided a detailed overview of the company’s financial performance, with key metrics including revenue, net income, and cash flow. The following table highlights some of the key data points from the call:
| Metric | Q4 2025 | Q4 2024 |
|---|---|---|
| Revenue | $10.2 million | $8.5 million |
| Net Income | $2.1 million | $1.5 million |
| Cash Flow | $5.6 million | $4.2 million |
The company’s financial performance was seen as a positive indicator of its future prospects, with $BWAY shares reacting favorably to the news.
Looking ahead, $BWAY is well-positioned to continue its growth trajectory, with a strong pipeline of products and a increasing demand for its TMS technology. As the company continues to expand its global reach and develop new products, it is likely to remain a key player in the healthcare technology sector.
⚡ Why it matters: BrainsWay Ltd.’s Q4 2025 earnings call provides insight into the company’s performance and future prospects, with implications for the broader healthcare sector. The company’s TMS technology has shown promise in treating various neurological and psychiatric disorders, and its growth trajectory is likely to continue in the coming years.
📊 By the numbers:
Revenue: $10.2 million
Net Income: $2.1 million
Cash Flow: $5.6 million
🔗 Source: [BrainsWay Ltd. Q4 2025 Earnings Call Transcript]*
